Tsh Biopharmoration Stock Beta
| 8432 Stock | TWD 69.80 1.50 2.20% |
tsh biopharmoration fundamentals help investors to digest information that contributes to Tsh Biopharmoration's financial success or failures. It also enables traders to predict the movement of Tsh Stock. The fundamental analysis module provides a way to measure Tsh Biopharmoration's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tsh Biopharmoration stock.
Tsh |
tsh biopharmoration Company Beta Analysis
Tsh Biopharmoration's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Tsh Biopharmoration Beta | -0.0266 |
Most of Tsh Biopharmoration's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, tsh biopharmoration is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, tsh biopharmoration has a Beta of -0.0266. This is 103.09% lower than that of the Healthcare sector and 102.27% lower than that of the Drug Manufacturers - Major industry. The beta for all Taiwan stocks is 82.27% lower than that of the firm.
Tsh Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tsh Biopharmoration's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tsh Biopharmoration could also be used in its relative valuation, which is a method of valuing Tsh Biopharmoration by comparing valuation metrics of similar companies.Tsh Biopharmoration is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Tsh Biopharmoration are expected to decrease at a much lower rate. During the bear market, Tsh Biopharmoration is likely to outperform the market.
Tsh Fundamentals
| Return On Equity | 0.0635 | |||
| Return On Asset | 0.0387 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 1.17 B | |||
| Shares Outstanding | 38.4 M | |||
| Shares Owned By Insiders | 64.94 % | |||
| Price To Earning | 56.63 X | |||
| Price To Book | 1.77 X | |||
| Price To Sales | 4.22 X | |||
| Revenue | 413.48 M | |||
| Gross Profit | 247.36 M | |||
| EBITDA | 71.41 M | |||
| Net Income | 47.11 M | |||
| Cash And Equivalents | 708.28 M | |||
| Cash Per Share | 18.36 X | |||
| Total Debt | 7.01 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 5.36 X | |||
| Book Value Per Share | 27.67 X | |||
| Cash Flow From Operations | 68.71 M | |||
| Earnings Per Share | 1.78 X | |||
| Number Of Employees | 80 | |||
| Beta | -0.0266 | |||
| Market Capitalization | 1.78 B | |||
| Total Asset | 1.17 B | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 3.54 % | |||
| Net Asset | 1.17 B | |||
| Last Dividend Paid | 1.5 |
About Tsh Biopharmoration Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze tsh biopharmoration's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tsh Biopharmoration using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of tsh biopharmoration based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Tsh Stock Analysis
When running Tsh Biopharmoration's price analysis, check to measure Tsh Biopharmoration's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tsh Biopharmoration is operating at the current time. Most of Tsh Biopharmoration's value examination focuses on studying past and present price action to predict the probability of Tsh Biopharmoration's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tsh Biopharmoration's price. Additionally, you may evaluate how the addition of Tsh Biopharmoration to your portfolios can decrease your overall portfolio volatility.